You may not have heard of these two subvariants before, but they now account for just over 7% of COVID cases in New England, according to the latest data. Here's what to know:
, with all of Connecticut, Massachusetts and Rhode Island now included in the medium risk category.
We asked Boston doctors for their thoughts on the new variants, and how worried people should be, during NBC10 Boston's weekly series, "In terms of this particular variant, the BQ.1.1, there's actually limited information that we actually have," said Dr. Sabrina Assoumou of Boston Medical Center."What we do know is it seems to have what we call a growth advantage, meaning it is quickly making up a higher proportion of the cases from COVID-19.
"Only time will tell," she said."My big message is, unfortunately, we're seeing more variants, and the virus is actually figuring out better ways to evade our protection, but we're not hopeless and it's not a helpless situation. We have vaccines, they actually work, but the key thing is that you have to be up to date... So please get get up to date so that we are all prepared in the community before a potential winter surge.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Comparison of Long-Term Complications of COVID-19 Illness among a Diverse Sample of Children by MIS-C StatusMost pediatric COVID-19 cases are asymptomatic; however, a small number of children are diagnosed with multisystem inflammatory syndrome in children (MIS-C), a rare but severe condition that is associated with SARS-CoV-2 infection. Persistent symptoms of COVID-19 illness in children diagnosed with/without MIS-C is largely unknown. A retrospective EHR review of patients with COVID-19 illness from one pediatric healthcare system to assess the presence of acute (<30 days) and chronic (≥30, 60–120, and >120 days) long-term COVID symptoms was conducted. Patients/caregivers completed a follow-up survey from March 2021 to January 2022 to assess the presence of long COVID. Results showed that non-MIS-C children (n=286; 54.49% Hispanic; 19.23% non-Hispanic Black; 5.77% other ethnicity; 79.49% government insurance) were younger (mean age 6.43 years [SD 5.95]) versus MIS-C (n=26) children (mean age 9.08 years, [SD 4.86]) (p=0.032). A share of 11.5% of children with MIS-C and 37.8% without MIS-C reported acute long COVID while 26.9% and 15.3% reported chronic long COVID, respectively. Females were almost twice as likely to report long symptoms versus males and those with private insurance were 66% less likely to report long symptoms versus those with government insurance. In conclusion, a substantial proportion of ethnically diverse children from low resource backgrounds with severe COVID illness are reporting long-term impacts. Findings can inform pediatric professionals about this vulnerable population in post-COVID-19 recovery efforts.
Read more »
Two cases of acute abdominal pain in patients with COVID-19 in their second week of illnessTwo cases of acute abdominal pain in patients with COVID-19 in their second week of illness JaypeeJournals pain coronavirus covid COVID19 illness
Read more »
Nottingham's Bonfire Night cancelled due to costsThis is just in: Nottingham's annual bonfire night and firework display at the Forest Recreation Ground has been cancelled
Read more »
Pathophysiology of Post-COVID syndromes: a new perspective - Virology JournalMost COVID-19 patients recovered with low mortality; however, some patients experienced long-term symptoms described as “long-COVID” or “Post-COVID syndrome” (PCS). Patients may have persisting symptoms for weeks after acute SARS-CoV-2 infection, including dyspnea, fatigue, myalgia, insomnia, cognitive and olfactory disorders. These symptoms may last for months in some patients. PCS may progress in association with the development of mast cell activation syndrome (MCAS), which is a distinct kind of mast cell activation disorder, characterized by hyper-activation of mast cells with inappropriate and excessive release of chemical mediators. COVID-19 survivors, mainly women, and patients with persistent severe fatigue for 10 weeks after recovery with a history of neuropsychiatric disorders are more prone to develop PCS. High D-dimer levels and blood urea nitrogen were observed to be risk factors associated with pulmonary dysfunction in COVID-19 survivors 3 months post-hospital discharge with the development of PCS. PCS has systemic manifestations that resolve with time with no further complications. However, the final outcomes of PCS are chiefly unknown. Persistence of inflammatory reactions, autoimmune mimicry, and reactivation of pathogens together with host microbiome alterations may contribute to the development of PCS. The deregulated release of inflammatory mediators in MCAS produces extraordinary symptoms in patients with PCS. The development of MCAS during the course of SARS-CoV-2 infection is correlated to COVID-19 severity and the development of PCS. Therefore, MCAS is treated by antihistamines, inhibition of synthesis of mediators, inhibition of mediator release, and inhibition of degranulation of mast cells.
Read more »
High TNF receptors levels could predict COVID-19 mortality and disease severityHigh TNF receptors levels could predict COVID-19 mortality and disease severity Mortality Coronavirus Disease COVID PLOSONE juntendo1838
Read more »
Transition in the management of COVID-19A review of the current approaches to managing COVID-19, including diagnostic, therapeutic, and preventive measures.
Read more »